Lin KW, Ang TL, Li JW. Role of artificial intelligence in early detection and screening for pancreatic adenocarcinoma. Artif Intell Med Imaging 2022; 3(2): 21-32 [DOI: 10.35711/aimi.v3.i2.21]
Corresponding Author of This Article
James Weiquan Li, FRCPE, MBBS, MMed, Assistant Professor, Doctor, Department of Gastroenterology and Hepatology, Changi General Hospital, 2 Simei Street 3, Singapore 529889, Singapore. james.li.w.q@singhealth.com.sg
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Artif Intell Med Imaging. Apr 28, 2022; 3(2): 21-32 Published online Apr 28, 2022. doi: 10.35711/aimi.v3.i2.21
Role of artificial intelligence in early detection and screening for pancreatic adenocarcinoma
Kenneth Weicong Lin, Tiing Leong Ang, James Weiquan Li
Kenneth Weicong Lin, Tiing Leong Ang, James Weiquan Li, Department of Gastroenterology and Hepatology, Changi General Hospital, Singapore 529889, Singapore
Author contributions: Lin KW performed the literature search and drafted the manuscript; Ang TL performed the literature search and was involved in the drafting of the manuscript; Li JW conceptualised the project, performed literature search and was involved in the drafting of the manuscript; all authors vetted and approved the final manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: James Weiquan Li, FRCPE, MBBS, MMed, Assistant Professor, Doctor, Department of Gastroenterology and Hepatology, Changi General Hospital, 2 Simei Street 3, Singapore 529889, Singapore. james.li.w.q@singhealth.com.sg
Received: December 16, 2021 Peer-review started: December 16, 2021 First decision: January 26, 2022 Revised: February 12, 2022 Accepted: March 16, 2022 Article in press: March 16, 2022 Published online: April 28, 2022
Abstract
Pancreatic adenocarcinoma remains to be one of the deadliest malignancies in the world despite treatment advancement over the past few decades. Its low survival rates and poor prognosis can be attributed to ambiguity in recommendations for screening and late symptom onset, contributing to its late presentation. In the recent years, artificial intelligence (AI) as emerged as a field to aid in the process of clinical decision making. Considerable efforts have been made in the realm of AI to screen for and predict future development of pancreatic ductal adenocarcinoma. This review discusses the use of AI in early detection and screening for pancreatic adenocarcinoma, and factors which may limit its use in a clinical setting.
Core Tip: Pancreatic adenocarcinoma has poor survival rate and high morbidity. Artificial intelligence is a potential tool to screen for high risk individuals and for early detection of pancreatic adenocarcinoma. Despite advances made in artificial intelligence research in pancreatic adenocarcinoma, it faces a number of challenges before it can be generalised and applied in a clinical setting.
